AndrewNava.com has added profiles for six new companies: Allon Therapeutics (NPC.TO), Conceptus (CPTS), PhotoMedex (PHMD), GenMark Diagnostics (GNMK), Neoprobe (NEOP) and QuantRX Biomedical (OTC:QTXB).
Our database is now tracking clinical and financial data from 299 publicly-traded healthcare companies. The database is updated daily and contains hundreds of clinical trial results, upcoming company milestones, sales data, key company financial information, deals and news summaries, and profies on over 1000 approved and development-stage drugs, devices and diagnostics.
Here's some key data on the new companies we added:
Allon Therapeutics (NPC.TO)
Primarily focusing on developing intranasal and intravenous formulations of Davunetide (tau inhibitor) for Progressive Supranuclear Palsy, Alzheimer’s disease, frontotemporal dementia, schizophrenia-related cognitive impairment. No near term catalysts. $33 million market cap.
Conceptus (CPTS)
Women's health company marketing the Essure device/procedure for permanent contraception. 1Q10 Essure sales: domestic sales $25.4 million (up 20% from 1Q09), international sales $8.0 million (up 33% from 1Q09) Cash: $99.3 million as of March 31, 2010. CPTS recently lowered its 2Q10 and 2010 sales guidance which tanked the stock 20%+. Earnings expected in August.
PhotoMedex (PHMD)
Dermatology company marketing light and laser devices for aesthetics and other skin diseases. Main brands include Lumiere, Omnilux Light Therapy, VTRAC Excimer Lamp System and XTRAC Lasers. No near term catalysts. $15.88 million market cap.
GenMark Diagnostics (GNMK)
Recent IPO. Develops and markets molecular diagnostics. Maker of the XT-8 System, a compact and easy-to-use workstation with self-contained, disposable test cartridges. FDA-approved diagnostic tests for use with the XT-8 System include Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test. GNMK is developing a Plavix Sensitivity and K-ras Mutation test and plans to complete a clinical trial for its Respiratory Viral Panel in 2010 with an FDA submission in 2011. $53 million market cap.
Neoprobe (NEOP)
Main development program is Lymposeek ([99mTc] DTPA-mannosyl-dextran), a radioactive tracing agent for use in breast cancer and melanoma. NEOP plans on submitting an NDA by the end of this summer, but not before requesting a formal pre-NDA meeting with the FDA to review the complete Lymphoseek regulatory package. NEOP will hold a conference call Monday, July 19th at 4:00 PM ET to provide a business update, discuss its product pipeline and provide an update on matters from the 2010 Annual Meeting of the Company’s stockholders scheduled for July 16th. $163 million market cap.
QuantRX Biomedical (OTC:QTXB)
Recently submitted a 510K for its Q-Reader Thyroid Testing System. $7.5 million market cap.
Andrew Nava LLC provides equity research services for both institutional and retail healthcare investors. We focus on fundamental research of small- to mid-cap healthcare companies with the potential for significant market cap appreciation in the next 6-12 months. Our investment theses are based on event-driven catalysts and value-driven growth.
Disclosure: No positions
Our database is now tracking clinical and financial data from 299 publicly-traded healthcare companies. The database is updated daily and contains hundreds of clinical trial results, upcoming company milestones, sales data, key company financial information, deals and news summaries, and profies on over 1000 approved and development-stage drugs, devices and diagnostics.
Here's some key data on the new companies we added:
Allon Therapeutics (NPC.TO)
Primarily focusing on developing intranasal and intravenous formulations of Davunetide (tau inhibitor) for Progressive Supranuclear Palsy, Alzheimer’s disease, frontotemporal dementia, schizophrenia-related cognitive impairment. No near term catalysts. $33 million market cap.
Conceptus (CPTS)
Women's health company marketing the Essure device/procedure for permanent contraception. 1Q10 Essure sales: domestic sales $25.4 million (up 20% from 1Q09), international sales $8.0 million (up 33% from 1Q09) Cash: $99.3 million as of March 31, 2010. CPTS recently lowered its 2Q10 and 2010 sales guidance which tanked the stock 20%+. Earnings expected in August.
PhotoMedex (PHMD)
Dermatology company marketing light and laser devices for aesthetics and other skin diseases. Main brands include Lumiere, Omnilux Light Therapy, VTRAC Excimer Lamp System and XTRAC Lasers. No near term catalysts. $15.88 million market cap.
GenMark Diagnostics (GNMK)
Recent IPO. Develops and markets molecular diagnostics. Maker of the XT-8 System, a compact and easy-to-use workstation with self-contained, disposable test cartridges. FDA-approved diagnostic tests for use with the XT-8 System include Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test. GNMK is developing a Plavix Sensitivity and K-ras Mutation test and plans to complete a clinical trial for its Respiratory Viral Panel in 2010 with an FDA submission in 2011. $53 million market cap.
Neoprobe (NEOP)
Main development program is Lymposeek ([99mTc] DTPA-mannosyl-dextran), a radioactive tracing agent for use in breast cancer and melanoma. NEOP plans on submitting an NDA by the end of this summer, but not before requesting a formal pre-NDA meeting with the FDA to review the complete Lymphoseek regulatory package. NEOP will hold a conference call Monday, July 19th at 4:00 PM ET to provide a business update, discuss its product pipeline and provide an update on matters from the 2010 Annual Meeting of the Company’s stockholders scheduled for July 16th. $163 million market cap.
QuantRX Biomedical (OTC:QTXB)
Recently submitted a 510K for its Q-Reader Thyroid Testing System. $7.5 million market cap.
Andrew Nava LLC provides equity research services for both institutional and retail healthcare investors. We focus on fundamental research of small- to mid-cap healthcare companies with the potential for significant market cap appreciation in the next 6-12 months. Our investment theses are based on event-driven catalysts and value-driven growth.
Disclosure: No positions